Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elsulfavirine + omeprazole
- Development stage
- Unknown
- Lead developer
- Viriom
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Elsulfavirine + omeprazole refers to the co-administration of the non-nucleoside reverse transcriptase inhibitor (NNRTI) elsulfavirine and the proton pump inhibitor (PPI) omeprazole. Elsulfavirine, developed by Viriom (a ChemRar company), is a prodrug of the active metabolite VM-1500A, designed for the treatment of HIV-1 infection. Omeprazole is a widely used agent for reducing gastric acid secretion by inhibiting the H+/K+-ATPase pump. This specific combination is primarily evaluated in clinical pharmacology trials to determine if the increased gastric pH caused by omeprazole affects the absorption and systemic exposure of elsulfavirine. Such studies are critical for NNRTIs, which often exhibit pH-dependent solubility and bioavailability, potentially leading to sub-therapeutic drug levels if co-administered with acid-reducing agents.
- Brand names
- ElpidaPrilosecLosec
- Other names
- elsulfavirineomeprazole
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseCA7 (Carbonic anhydrase VII)
Beyond the preview
Go deeper on elsulfavirine + omeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elsulfavirine + omeprazole.